FindTrial
Sign In

Study on presence of viral markers in neck lymph nodes in head and neck cancers(namely cancers of unknown primary , oropharynx and nasopharynx)

Detection of oncogenic viruses HPV and EBV by immunohistochemistry in secondary cervical lymph nodes from primary of oropharynx, nasopharynx and unknown primary

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2020/09/027522
Enrollment
50
Registered
2020-09-01
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C119- Malignant neoplasm of nasopharynx,unspecified Health Condition 2: C10- Malignant neoplasm of oropharynx Health Condition 3: C799- Secondary malignant neoplasm of unspecified site

Interventions

Intervention1: NIL: NIL Control Intervention1: NIL: NIL

Sponsors

Dept of Otorhinolaryngology and Head and Neck Surgery
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1).All patients with cytologically or histologically proven metastatic squamous cell carcinoma , poorly differentiated and undifferentiated carcinoma to cervical lymph nodes in whom a primary lesion cannot be identified after a thorough routine examination of oral cavity, oropharynx, hypopharynx, nasopharynx and larynx in ENT OPD, including by nasal endoscopy, fibre optic/rigid telescopic examination of oropharynx, hypopharynx and larynx, and lacking an enhancing lesion/ definite mass suspicious of the primary on Contrast Enhanced Computed Tomography/Magnetic Resonance Imaging (MRI) from the skull base to the thoracic inlet (T4). 2).All cases of biopsy proven oropharyngeal carcinoma with cervical lymph node metastases 3).All cases of biopsy proven nasopharyngeal carcinoma with cervical lymph node metastases 4).Patient giving consent to participate in study

Exclusion criteria

Exclusion criteria: 1).Patient who is not willing to participate in the study 2).Patient who is unfit for surgery under general anesthesia 3).Severe claustrophobia. 4).Pregnancy 5).H/o anaphylactoid reactions with intravenous contrast for CT/ FDG for PET. 6).Presence of distant metastasis on 18FDG-PET-CT 7).Cases without adequate tissue in the FFPE block to perform IHC

Design outcomes

Primary

MeasureTime frame
1).To know the prevalence of Human Papilloma Virus (HPV) in the cases of metastatic squamous cell carcinoma to cervical lymph nodes without a clinically or radiologically detected primary lesion in head and neck. 2).To know the prevalence of Human Papilloma Virus (HPV) in cervical lymph node metastases from primary of oropharynx. 3).To know the prevalence of Epstein Barr Virus (EBV-LMP1) in cervical lymph node metastases from primary of nasopharynx. Timepoint: 4 weeks to 8 weeks—

Secondary

MeasureTime frame
To determine the HPV and EBV prevalence in India in cases of Carcinoma of unknown primary,CA nasopharynx and CA oropharynxTimepoint: 4 weeks to 8 weeks—

Countries

India

Contacts

Public ContactHarithraa C B

All India Institute of Medical Sciences

amitchirom@gmail.com9999501928

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026